InMode (INMD) Q2 2025: International Sales Hit 48% of Mix as U.S. Headwinds Persist
InMode’s Q2 revealed a decisive shift toward international markets, with non-U.S. sales nearing parity and Europe delivering record results. The company’s core minimally invasive platforms remain dominant, but macro-driven demand softness in North America continues to weigh on growth and prompted a guidance reduction. Management’s refusal to cut R&D or sales headcount signals a conviction in long-term innovation and global expansion, even as near-term visibility remains clouded.
Summary
- International Expansion Accelerates: Overseas sales mix reached 48%, driven by Europe’s record contribution and new direct operations.
- Product Mix Shifts Under Macro Pressure: Non-invasive platform growth offset softness in higher-priced minimally invasive procedures.
- Guidance Reset Reflects Prolonged U.S. Demand Weakness: Leadership maintains investment in sales and R&D, betting on recovery and regulatory catalysts.
Performance Analysis
InMode’s Q2 results underscore the company’s resilience in a challenging environment, with total revenue landing at $95.6 million and international markets now accounting for nearly half of sales. Europe emerged as the largest regional contributor, hitting a record $23 million, reflecting management’s intensified focus on global direct sales and distribution. The company’s minimally invasive platforms, which include body-tight and Morpheus systems, made up 84% of total revenue, but the quarter also saw a notable uptick in non-invasive platform sales, partially attributed to the launch of Optimus Max.
Gross margin remained robust at 80%, highlighting the company’s premium positioning and cost control, though operating expenses climbed 5% on continued investment in sales and marketing. Despite macro headwinds, operating margin expanded to 24% GAAP (28% non-GAAP), and net income grew modestly. The company generated $24 million in operating cash flow and ended the quarter with over $510 million in cash and equivalents, preserving ample flexibility for capital allocation.
- Geographic Mix Shift: Non-U.S. sales grew 11% year over year, now representing 48% of total revenue, compared to a historical 60-65% U.S. weighting.
- Product Mix Evolution: Non-invasive platforms saw outsized growth as consumer spending shifted away from higher-cost minimally invasive procedures.
- Operating Leverage Maintained: Margin expansion was achieved despite higher sales and marketing expense, aided by lower share-based compensation and strong gross margin retention.
Management’s guidance cut reflects two consecutive quarters of underperformance versus expectations, with both Q1 and Q2 falling short of original internal targets due to persistent demand softness in North America and only modest improvement in consumables trends.
Executive Commentary
"We continue to navigate a challenging medical aesthetic market, especially in North America, due to reduced personal spending. This environment results in fewer treatments and less capital investment from physicians. Building on the strategy we outlined last year, we have started restructuring key part of our sales team to drive deeper market penetration."
Moshe Mizrahi, CEO
"GAAP operating margin was 24%, up from 21% in the second quarter of 2024. On a non-GAAP basis, operating margin reached 28% compared to 27% last year. As part of our global expansion, we currently have a direct sales force of over 297 representatives and distributors coverage in more than 74 countries."
Yair Malka, Chief Financial Officer
Strategic Positioning
1. International Diversification and Direct Market Entry
InMode has accelerated its pivot toward international markets, launching new direct operations in Thailand and Argentina to reduce reliance on distributors and improve local support. This strategy is already yielding results, with Europe setting a new revenue record and the overall mix shifting to a 50-50 split between U.S. and ex-U.S. sales, a significant departure from prior years. Management sees international as a durable growth engine, with plans to continue this direct expansion model.
2. Product Portfolio Adaptation and Innovation
The company is adapting to macro pressures by emphasizing non-invasive platforms, such as Optimus Max, which addresses price-sensitive consumer segments and lower procedural costs for providers. While minimally invasive remains the core (84% of revenue), the non-invasive segment is gaining share, supported by new product cycles and incremental launches. The upcoming wellness and urology platforms, though not expected to materially impact 2025, represent a pipeline of future growth tied to regulatory milestones.
3. Relentless R&D and Sales Force Investment
Despite near-term revenue softness, InMode is maintaining investment in R&D and sales headcount, betting that innovation and market coverage will pay off when demand rebounds. Leadership explicitly rejected cost-cutting in engineering and sales, viewing these teams as critical assets for long-term competitive positioning, especially as new indications and regulatory approvals unlock new market segments.
4. Capital Allocation Flexibility
With over $510 million in cash, management is weighing further buybacks, dividends, or opportunistic M&A, but is constrained by Israeli tax considerations and a lack of attractive acquisition targets. The company has already repurchased over $500 million of shares in the past two years, and all capital return options remain on the table for the next six months.
5. Regulatory and Tariff Navigation
Tariff uncertainty remains a watchpoint, with current U.S. tariffs on Israeli imports temporarily reduced to 10% (from 17%). Management expects a 2-3% annualized margin impact if tariffs persist, but is pursuing strategic supply chain adjustments to mitigate the hit. Regulatory progress on urology and ophthalmology indications could unlock new growth vectors in 2026 and beyond.
Key Considerations
This quarter’s results highlight a company in transition, balancing near-term macro headwinds with long-term bets on innovation and international expansion. Investors should weigh the durability of international growth, the evolving product mix, and management’s conviction in maintaining investment through the cycle.
Key Considerations:
- International Outperformance: Europe’s record quarter and new direct offices are shifting revenue mix and reducing U.S. dependency.
- Product Mix Sensitivity: Non-invasive platform growth is offsetting some demand softness, but minimally invasive remains the profit engine.
- Guidance Reset Signals Caution: Lowered full-year outlook reflects persistent U.S. demand weakness and conservative planning for H2.
- Capital Allocation Optionality: Large cash balance supports flexibility, but buybacks and dividends face tax headwinds and lack of near-term M&A targets.
- Regulatory Catalysts on Horizon: Approvals for urology and ophthalmology platforms could drive step-change growth, but timing remains uncertain.
Risks
Persistent macroeconomic pressure in North America, delayed capital purchases by providers, and consumer discretionary weakness remain the dominant risks. Tariff volatility and regulatory delays could further compress margins or stall new platform launches. Management’s refusal to cut core R&D and sales costs could pressure near-term profitability if demand does not recover as anticipated.
Forward Outlook
For Q3, InMode expects:
- Continued 50-50 U.S. and international sales mix
- Minimal revenue contribution from new urology and wellness platforms
For full-year 2025, management lowered guidance to:
- Revenue of $365 million to $375 million
- Non-GAAP operating income of $93 million to $98 million
- Non-GAAP EPS of $1.55 to $1.59
Management cited sustained U.S. market weakness, unchanged customer behavior, and a slow capital equipment cycle as drivers for the reset. They emphasized continued investment in sales and R&D, and flexibility to raise guidance if demand rebounds.
- Monitoring tariff negotiations and regulatory progress for potential upside
- Expecting minimal initial impact from new platform launches in Q4
Takeaways
InMode’s Q2 highlights the company’s ability to defend margins and pivot geographically, even as North American demand remains subdued. International growth and product innovation are offsetting some macro softness, but visibility remains limited until U.S. capital spending recovers.
- International Diversification: Europe and new direct markets are increasingly central to the growth narrative, reducing geographic risk.
- Resilient Margins: Industry-leading gross margins and disciplined cost management support profitability, even with higher sales investment.
- Pipeline-Driven Optionality: Regulatory wins in urology and ophthalmology, along with further product cycles, could catalyze a new growth phase, but timing is uncertain.
Conclusion
InMode is weathering a tough U.S. market by doubling down on international expansion, innovation, and margin discipline. The company’s conviction in long-term growth, supported by a strong balance sheet and global reach, positions it well for a cyclical recovery, but near-term caution is warranted as macro and regulatory risks persist.
Industry Read-Through
InMode’s results offer a clear read-through for the broader medical aesthetics sector: International diversification and direct sales models are increasingly critical as U.S. capital spending stagnates. Product mix flexibility—shifting toward lower-cost, non-invasive treatments—can help offset macro-driven volume declines, but premium procedural segments remain sensitive to consumer sentiment. Tariff and regulatory uncertainty are sector-wide challenges, reinforcing the need for operational agility and robust balance sheets. Investors should watch for similar geographic and product mix pivots across the industry as companies adapt to prolonged demand softness in North America.